PMP22 and Charcot-Marie-Tooth disease type 1A: For example, CRISPR/Cas9 was used to directly target the PMP22 gene by deleting its regulatory regions with encouraging results in vitro (62) and in vivo (63), and oligonucleotides have been tested to inhibit PMP22 via promoter disruption or through mRNA degradation using RNAase H or RNAi-based mechanisms (using DNA gapmers or siRNAs, respectively) in different CMT1A rodent models (64–67).